Centessa Pharmaceuticals plc Cash Flow Statement
CNTA / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
Centessa Pharmaceuticals plc used $194M in operating cash flow and negative free cash flow of $194M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.80 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$197.5M | -$235.8M | -$151.1M | -$216.2M | -$381.1M | -$10.7M | -$5.1M |
| Depreciation & Amortization | $921.0K | $942.0K | $810.0K | $131.0K | $34.0K | $0 | $6.0K |
| Operating Cash Flow | -$193.8M | -$142.1M | -$160.3M | -$200.5M | -$135.1M | -$10.6M | -$5.8M |
| Capital Expenditures | $371.0K | $34.0K | $169.0K | $1.1M | $186.0K | $0 | $0 |
| Free Cash Flow | -$194.2M | -$142.1M | -$160.5M | -$201.7M | -$135.3M | -$10.6M | -$5.8M |
| Share Buybacks | - | - | - | - | $12.0K | $0 | $0 |
| FCF Margin | -1294.6% | - | -2342.2% | - | - | - | - |